Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor IIA subunit 1-like (GTF2A1L) encodes a germ cell-specific large (alpha/beta) subunit of general transcription factor TFIIA, important for the assembly and stability of the RNA polymerase II transcription pre-initiation complex in eukaryotes[1][2][10]. It functions by stabilizing the interaction between TATA-binding protein (TBP) and DNA, working in conjunction with GTF2A2, and is believed to be essential for transcription in the testis, potentially contributing to spermatogenesis and testis-specific gene expression[1][4][10]. Alternative splicing generates distinct isoforms, and a rare fusion transcript (SALF) has been described[1][2]. While GTF2A1L is implicated in some Mendelian disease phenotypes,[2] it is not broadly recognized as a direct therapeutic target or a receptor/enzyme classically targeted by drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor IIA subunit 1-like (GTF2A1L).